JP2015526497A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526497A5
JP2015526497A5 JP2015529082A JP2015529082A JP2015526497A5 JP 2015526497 A5 JP2015526497 A5 JP 2015526497A5 JP 2015529082 A JP2015529082 A JP 2015529082A JP 2015529082 A JP2015529082 A JP 2015529082A JP 2015526497 A5 JP2015526497 A5 JP 2015526497A5
Authority
JP
Japan
Prior art keywords
medicament according
selective agonist
brl37344
pharmaceutically acceptable
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015529082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526497A (ja
JP6539206B2 (ja
Filing date
Publication date
Priority claimed from ES201231343A external-priority patent/ES2394349B1/es
Application filed filed Critical
Publication of JP2015526497A publication Critical patent/JP2015526497A/ja
Publication of JP2015526497A5 publication Critical patent/JP2015526497A5/ja
Application granted granted Critical
Publication of JP6539206B2 publication Critical patent/JP6539206B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015529082A 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用 Expired - Fee Related JP6539206B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201231343 2012-08-29
ES201231343A ES2394349B1 (es) 2012-08-29 2012-08-29 Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
PCT/ES2013/070611 WO2014033343A1 (es) 2012-08-29 2013-08-28 Agonistas de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar

Publications (3)

Publication Number Publication Date
JP2015526497A JP2015526497A (ja) 2015-09-10
JP2015526497A5 true JP2015526497A5 (https=) 2016-10-13
JP6539206B2 JP6539206B2 (ja) 2019-07-03

Family

ID=47520452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529082A Expired - Fee Related JP6539206B2 (ja) 2012-08-29 2013-08-28 肺高血圧症の治療のためのベータ−3アドレナリン受容体アゴニストの使用

Country Status (6)

Country Link
US (1) US10532038B2 (https=)
EP (1) EP2891490B1 (https=)
JP (1) JP6539206B2 (https=)
DK (1) DK2891490T3 (https=)
ES (2) ES2394349B1 (https=)
WO (1) WO2014033343A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
EP4313019A4 (en) * 2021-03-31 2025-02-12 B3AR Therapeutics, Inc. Compositions of micronized solabegron and methods of use
IT202300021417A1 (it) 2023-10-13 2025-04-13 Univ Pisa Agonisti o attivatori del recettore adrenergico beta-3

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2965655D1 (en) 1978-06-28 1983-07-21 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
ATE1899T1 (de) 1979-06-16 1982-12-15 Beecham Group Plc Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
US4338333A (en) 1979-06-16 1982-07-06 Beecham Group Limited Ethanamine derivatives their preparation and use in pharmaceutical compositions
PT82120B (en) 1985-03-01 1988-06-16 Beecham Group Plc Process for preparing veterinary formulations containing ethanolamine derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
IT1204416B (it) 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
EP0403360B1 (fr) 1989-06-13 1996-10-16 Sanofi Utilisation de phényléthanolamines pour la préparation de médicaments pour les affections oculaires
GB8925032D0 (en) 1989-11-06 1989-12-28 Ici Plc Chemical compounds
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
ES2139633T3 (es) 1992-08-31 2000-02-16 Sankyo Co Derivados de oxazolidina con propiedades anti-diabetica y anti-obesidad, su preparacion y su utilizacion terapeutica.
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
IL113084A (en) 1994-03-23 1999-01-26 Sankyo Co Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
DE69521529T2 (de) 1994-11-29 2001-10-11 Dainippon Pharmaceutical Co., Ltd. Indolderivat
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
DK0764632T3 (da) 1995-09-21 2001-09-24 Lilly Co Eli Selektive beta3-adrenerge agonister
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1997015549A1 (en) 1995-10-26 1997-05-01 Tokyo Tanabe Company Limited PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME
CN1083831C (zh) 1996-01-10 2002-05-01 旭化成株式会社 新的三环化合物及含有它们的药物组合物
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
ID22273A (id) 1997-01-28 1999-09-23 Merck & Co Inc TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS
ES2149742T1 (es) 1997-07-03 2000-11-16 Asahi Chemical Ind Nuevos compuestos triciclicos que tienen anillos saturados y composiciones medicinales que contienen los mismos.
EP1303509B1 (en) 2000-07-13 2012-11-28 Eli Lilly And Company Beta3 adrenergic agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US20040242485A1 (en) 2003-05-30 2004-12-02 Takashi Kadowaki Compositions and methods for the amelioration of leptin resistance
DK3459558T3 (da) * 2010-06-25 2020-11-02 Univ Aston Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
CN102764438A (zh) * 2012-01-30 2012-11-07 林曙光 β3肾上腺素受体激动剂的新用途

Similar Documents

Publication Publication Date Title
JP2018024670A5 (https=)
JP2018520455A5 (https=)
JP2017514910A5 (https=)
JP2018024682A5 (https=)
JP2011518833A5 (https=)
JP2016056183A5 (https=)
JP2009535462A5 (https=)
JP2012530705A5 (https=)
JP2011500550A5 (https=)
JP2014515013A5 (https=)
JP2017528503A5 (https=)
JP2013032389A5 (https=)
JP2009502793A5 (https=)
JP2014062126A5 (https=)
JP2013521295A5 (https=)
JP2013532130A5 (https=)
JP2012513416A5 (https=)
JP2011513410A5 (https=)
JP2015199738A5 (https=)
JP2017511377A5 (https=)
JP2012507535A5 (https=)
JP2015512883A5 (https=)
JP2010521516A5 (https=)
JP2016529306A5 (https=)
JP2018530608A5 (https=)